Rontalizumab
Jump to navigation
Jump to search
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | IFN-α |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6486H9990N1722O2026S44 |
| Molar mass | 145.9 kg/mol |
  (what is this?) (verify) | |
Rontalizumab is a humanized monoclonal antibody[1] being developed by Genentech.[2] As of November 2009[update], it is being investigated in a clinical trial for the treatment of systemic lupus erythematosus.[3]
References[edit]
- ^ WHO Drug Information
- ^ Genentech: Rontalizumab (rhuMAb IFN alpha)
- ^ Clinical trial number NCT00962832 for "A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (ROSE)" at ClinicalTrials.gov
 | This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
